After the Federal Reserve’s policy-making committee detailed it plans to stay calm and watch the data as it reached a decision when to elevate interest rates, U.S Stock shattered sentiment, over the course of the trading day on Wednesday.
Shimmering the sharp drop by the price of crude oil, energy stocks saw considerable weakness throughout much of the trading session.
Biotechnology, financial, airline and chemical stocks also moved remarkably lower on the day, sparkling the broad based weakness that come forward on Wall Street.
The main focus of this article is to share financials along with latest news and profiles, of such biotech sector companies, which ended their Wednesday trading session, in a deep red zone.
In biotech sector, Celldex Therapeutics, Inc. (NASDAQ:CLDX), declined -6.07%, during its last trade, closing at $22.27. Its total traded volume was $2,204,776 shares as compared to average volume of $2,986,900. The company has market cap of $2.00B.
Celldex Therapeutics, Inc. (NASDAQ:CLDX), a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel therapeutics for human health care primarily in the United States.
Advaxis, Inc. (NASDAQ:ADXS), plunged -7.38% to settle at $9.16, during its last trading session, as a clinical-stage biotechnology company developing cancer immunotherapies, declared an update related to the Phase 2 open-label clinical study of ADXS-HPV (ADXS11-001) in patients with persistent or recurrent cervical cancer with documented disease progression being conducted by the Gynecologic Oncology Group (GOG), now part of NRG Oncology. The study, known as GOG 0265, has accomplished its first stage and has met the predetermined safety and efficacy criteria required to proceed into the second stage of patient enrollment. This trial is being conducted in the U.S. by the GOG, under the sponsorship of the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI).
Advaxis, Inc. (NASDAQ:ADXS), is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm-LLO platform technology.
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), dipped -3.96% to $14.81, trading in a range of $14.55 - $15.70, Its total traded volume was $4,263,886 shares as compared to average volume of $7,083,730. The company has market cap of $1.48B.
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), a biopharmaceutical company, discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally.
Celgene Corporation, (NASDAQ:CELG), dwindled -2.77% to close at $118.97, during its last trade, as an integrated global biopharmaceutical company, plans to present at two forthcoming investor conferences where Celgene administration will offer an overview of the Company. The conferences will be webcast live and will be accessible in the Investor Relations section of the Company’s website at www.celgene.com.
Wednesday, February 11, 2015, Celgene will present at the Leerink Global Healthcare Conference in New York City at 11:30 am ET.
Tuesday, February 24, 2015, Celgene will present at the RBC Capital Markets’ Global Healthcare Conference in New York City at 8:00 am ET.
Celgene Corporation, (NASDAQ:CELG), headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation.
